B

Front 1

whohave favorable pregnancy outcomes.

Back 1

Patients with systemic lupus erythematosus whose disease has been quiescent for at least 6 months before conception and who either take no medications or take medications that can be continued during pregnancy typically have favorable pregnancy outcomes.
*

Front 2

increases the risk for preeclampsia in pregnant patients with systemic lupus erythematosus.

Back 2

Disease activity, particularly renal manifestations, increases the risk for preeclampsia in pregnant patients with systemic lupus erythematosus.
*

Front 3

Antiphospholipid antibodies predispose patients with systemic lupus erythematosus to

Back 3

Antiphospholipid antibodies predispose patients with systemic lupus erythematosus to both intrapartum and postpartum venous and arterial thromboses and are associated with second- and third-trimester pregnancy losses.
*

Front 4

Neonatal lupus affects 1% to 2% of children of mothers with anti-Ro/SSA or anti-La/SSB antibodies, independent of w

Back 4

Neonatal lupus affects 1% to 2% of children of mothers with anti-Ro/SSA or anti-La/SSB antibodies, independent of whether these women have systemic lupus erythematosus or Sjögren syndrome.
*

Front 5

Neonatal lupus can cause in utero

Back 5

Neonatal lupus can cause in utero fetal heart block and postnatal rash and hematologic and hepatic abnormalities.
*

Front 6

warrant closer follow-up.

Back 6

In patients with systemic lupus erythematosus, an increase in anti–double-stranded DNA antibody titers and a decrease in complement levels warrant closer follow-up.

Front 7

* Systemic lupus erythematosus is a risk factor for

Back 7

* Systemic lupus erythematosus is a risk factor for premature atherosclerosis, death from coronary artery dise-ase, and hematologic malignancy.